Matthew I. Mace Joins Precision Cardiovascular's Board
Precision Cardiovascular (PCV), an innovator in next-generation cardiac health solutions, has made a significant addition to its Board of Directors with the appointment of Matthew I. Mace, B.Sc. Mace is an AHCS-accredited Clinical Physiologist renowned for his strategic insight in the medtech field. This appointment aligns with the company's commitment to enhancing its clinical development as it transitions from pre-clinical to clinical stages.
Expertise in Cardiovascular Technologies
Matthew Mace brings over 15 years of extensive experience, particularly focused on both invasive and non-invasive cardiovascular technologies. His previous role as the UK & Ireland Product Manager at Abbott saw him leading the commercialization of critical cardiac resilience technologies, including Cardiac Resynchronisation Therapy (CRT) devices. He was instrumental in the launch of the UK's inaugural CardioMEMS HF monitoring sites, significantly contributing to market share gains in cardiac rhythm management devices.
Innovative Contributions to Medtech
As the Chief Scientific Officer and Co-Founder of Acorai, Matthew spearheaded groundbreaking initiatives that achieved FDA Breakthrough designation for their machine-learning driven intracardiac pressure reader. This accomplishment secured substantial funding and initiated global trials involving thousands of patients across multiple nations. His leadership extended to Circle Cardiovascular Imaging (CVI), where he played a central role in marketing and sales strategies, resulting in a remarkable increase in the annual revenue of over $50 million within just 18 months.
Strategic Vision for the Future
Matthew’s regulatory acumen is another asset for Precision Cardiovascular, with previous successes in navigating critical regulatory approvals. His strategic insight into FDA TAP program access and EU CE-marking strategies bolster the company’s efforts to ensure product safety and efficacy, a priority as PCV moves toward significant clinical trials. His experience in establishing quality systems for both startups and large-scale medtech enterprises will be invaluable.
PCV's Commitment to Advancing Cardiac Care
Matthew Mace expressed optimism about his new role, stating, "Precision Cardiovascular stands at a key moment, bridging cutting-edge research with real-world clinical impact. I'm honoured to contribute to its journey toward clinical validation and global adoption." This sentiment echoes the company's strategic vision, as noted by CEO Mohamed Abou-Alam, who views Matthew's dual expertise as a crucial element for successfully navigating the complexities of regulatory landscapes.
The appointment arrives as Precision Cardiovascular intensifies its pre-clinical efforts, particularly in developing minimally invasive haemodynamic monitoring solutions. With an ambitious plan to launch first-in-human trials for its pioneering sensor technology within the next couple of years, the company is poised to redefine cardiac care with its innovative approaches.
About Precision Cardiovascular
Precision Cardiovascular designs and develops advanced remote monitoring solutions aimed at revolutionizing heart failure management. Its cutting-edge technology combines advanced sensors with machine learning to facilitate reliable, proactive cardiac care across diverse settings. Notably, the Precision Cardiovascular system remains investigational and has not yet received clearance for clinical use in any region.
Frequently Asked Questions
What role will Matthew Mace play at Precision Cardiovascular?
Matthew Mace will serve on the Board of Directors, bringing his extensive expertise in clinical development and regulatory strategy to support the company’s transition to clinical stages.
What industry experience does Matthew Mace have?
Matthew Mace has over 15 years of experience in both invasive and non-invasive cardiovascular technologies and has held key roles at companies like Abbott, Acorai, and Circle Cardiovascular Imaging.
How will Mace's expertise benefit Precision Cardiovascular?
His background in regulatory approvals and commercial leadership is essential for guiding the company's products through complex regulatory processes and enhancing market strategies.
What is the focus of Precision Cardiovascular's technology?
The company focuses on developing remote monitoring solutions for heart failure management, integrating advanced sensor technology with machine learning for proactive cardiac care.
What is the current status of the Precision Cardiovascular system?
The Precision Cardiovascular system is currently investigational and not yet cleared for clinical use, indicating ongoing research and development efforts.
